2-Hydroxybenzylamine, a potent small molecule scavenger of IsoLGs, sequesters the reactive species as inert adducts. 2-Hydroxybenzylamine may be used to decrease early recurrence of atrial fibrillation and other atrial arrhythmias following atrial fibrillation ablation by decreasing IsoLG adducts with native biomolecules.

Compared to hypercholesterolemic Ldlr-/- mice treated with vehicle or 4-Hydroxybenzylamine, a nonreactive analogue, 2-Hydroxybenzylamine decreases atherosclerosis by 60% in en face aortas, without changing plasma cholesterol. Ldlr-/- mice treated with 2-Hydroxybenzylamine have reduced MDA-LDL and MDA-HDL levels, and their HDL display increased capacity to reduce macrophage cholesterol. Importantly, 2-Hydroxybenzylamine reduces the MDA- and IsoLG-lysyl content in atherosclerotic aortas versus 4-Hydroxybenzylamine. Furthermore, 2-Hydroxybenzylamine reduces inflammation and plaque apoptotic cells and promotes efferocytosis and features of stable plaques. Dicarbonyl scavenging with 2-Hydroxybenzylamine has multiple atheroprotective effects in a murine FH model[2].